ORIGINAL RESEARCH article

Front. Pharmacol., 14 January 2021

Sec. Ethnopharmacology

Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.580978

An Integrated Strategy for Effective-Component Discovery of Astragali Radix in the Treatment of Lung Cancer

  • BY

    Bing Yang 1,2,3

  • NY

    Nan Yang 1

  • YC

    Yaping Chen 1,3

  • MZ

    Maomao Zhu 1,3

  • YL

    Yuanpei Lian 1,3

  • ZX

    Zhiwei Xiong 1,3

  • BW

    Bei Wang 1,3

  • LF

    Liang Feng 1,3*

  • XJ

    Xiaobin Jia 1,2,3*

  • 1. School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China

  • 2. Nanjing University of Chinese Medicine, Nanjing, China

  • 3. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

Article metrics

View details

39

Citations

5,8k

Views

3,2k

Downloads

Abstract

Lung cancer is one of the most devastating diseases worldwide, with high incidence and mortality worldwide, and the anticancer potential of traditional Chinese medicine (TCM) has been gradually recognized by the scientific community. Astragali Radix (AR) is commonly used in traditional Chinese medicine in the treatment of lung cancer and has a certain clinical effect, but effective components and targets are still unclear. In the study, we established an integrated strategy for effective-component discovery of AR in the treatment of lung cancer based on a variety of techniques. First, the effective components and potential targets of AR were deciphered by the “component-target-disease” network using network pharmacology, and potential signal pathways on lung cancer were predicted by Gene Ontology (GO) biological function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Then, the therapeutic effects of AR in the treatment of lung cancer were evaluated in vivo using A/J mice, and the potential targets related to autophagy and potential signal pathway were verified by Western blot analysis, immunofluorescence staining, and real-time PCR technology at protein and gene expression level. Finally, metabolism in vitro by rat intestinal flora and cell membrane immobilized chromatography technology were used to screen the effective components of AR in the treatment of lung cancer, and remaining components from the cell immobilized chromatography were collected and analyzed by ultra-performance liquid chromatography–electrospray quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). The screening results of the integrated strategy showed that calycosin-7-O-β-D-glucoside, ononin, calycosin, astragaloside IV, astragaloside II, cycloastragenol, and formononetin may be effective components of AR in the treatment of lung cancer, and they may play a role in the treatment of lung cancer through autophagy and p53/AMPK/mTOR signaling pathway. The integrated strategy for effective-component discovery provided a valuable reference mode for finding the pharmacodynamic material basis of complex TCM systems. In addition, the prediction for targets and signal pathways laid a foundation for further study on the mechanism of AR in the treatment of lung cancer.

Introduction

As a global health burden, lung cancer is the highest incidence cancer at present (Torre et al., 2015; Wang et al., 2019). According to relevant statistics, lung cancer accounts for 19.4% of cancer-related deaths with 1.59 million deaths each year, which seriously endangers human health (Ke et al., 2019). As estimated by the International Agency for Research on Cancer, the number of deaths caused by lung cancer will raise to 10 million deaths per year by 2030 (Lou et al., 2016). However, the existing therapies, including radiotherapy, chemotherapy, and the emerging target therapy, are still unsatisfactory to improve the survival of lung cancer patients during the last 30 years (Cheng et al., 2018). So, it is an urgently required issue to achieve a breakthrough in medical treatment of lung cancer.

In recent years, the anticancer potential of traditional Chinese medicine (TCM) has been gradually recognized by the scientific community (Jiang et al., 2017; Zhu et al., 2019). In China, TCM is widely used in the treatment of cancer by preventing tumorigenesis, attenuating the toxicity, enhancing the therapeutic effect of radiotherapy and chemotherapy, reducing tumor recurrence, etc. (Wang et al., 2018; Zhang et al., 2018). Astragali Radix (AR), a well-known TCM, is the dried root of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. has been used as a common clinical medicine in China for thousands of years. The accumulated data showed that AR was beneficial for the treatment of lung cancer in clinical practice (He et al., 2013; Xiao et al., 2019). However, the effective components and potential targets of AR in the treatment of lung cancer have not been reported.

Network pharmacology is a discipline for investigating pathogenesis of disease through constructing and analyzing biological networks (Chen et al., 2019), and provides a powerful tool for screening effective components and potential targets of TCM by establishing a “component-target-disease” network. Modern pharmacological research has proved that the combination of drugs with the lipid bilayer, receptors, and enzymes on the cell membrane is a main mechanism of drug action. Therefore, the effective components can be screened according to the affinity between the components and the cell membrane. Cell membrane immobilized chromatography, as a kind of cell membrane chromatography, uses active cells as the separation vector, TCM extracts as the object, and the separation was carried out according to whether the ingredients in the extract have specific affinity with the cells. In the study, we established an integrated strategy for effective-component discovery of AR in the treatment of lung cancer based on a variety of techniques, and investigated the relationship between autophagy and the anticancer effect of AR in vitro and in vivo.

Materials and Methods

Materials and Reagents

AR was obtained from Anhui Jingquan Group Herbal Pieces Co., Ltd (Anqing city, Anhui Province, China) and was identified by De-kang Wu (professor of Nanjing University of traditional Chinese medicine) as the dried root of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.). Benzopyrene was purchased from Aladdin Reagent Co., Ltd. (Shanghai, China). Cisplatin (DDP, 1 mg/ml, 20 ml) was gained from Nanjing pharmaceutical factory Co., Ltd. (Nanjing, China). 4% paraformaldehyde fixative was purchased from Nanjing Nanao Technology Co., Ltd. (Nanjing, China). Hematoxylin dyeing solution (D005) was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Eosin dye solution (KGA231), 0.25% trypsin, 1% Triton X-100, goat serum, 4’,6-diamidino-2-phenylindole, and DMEM high glucose medium were purchased from Nanjing KeyGen Biotech logical Co., Ltd. (Nanjing, China). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 0802) antibody was purchased from Shanghai Kangcheng Biological Engineering Co., Ltd. (Shanghai, China). The antibodies against protein 53 (p53, ab131442), phosphorylated B-cell lymphoma-2 (p-Bcl-2, ab138406), mammalian target of rapamycin (mTOR, ab2732), AMP-activated protein kinase (AMPK, ab32047) and Beclin1 (ab133357) were obtained from Abcam (Cambridge, United Kingdom). NP-40 lysis buffer (1210600) was purchased from Nanjing Shengxing Biotechnology Co., Ltd. (Nanjing, China). Polyvinylidene fluoride (k8JN62911) was purchased from Millipore Corporation (Bedford, MA, USA). Pre-stained protein marker was purchased from Fermentas (Burlington, Canada).

Astragaloside I (MUST-16012906) and astragaloside II (MUST-16031010) were purchased from manster biotechnology Co., Ltd. (Chengdu, China). Cycloastragenol (HHQC20170921) was purchased from Nanjing Spring and Autumn Biological Engineering Co., Ltd. (Nanjing, China). Astragaloside IV (1107781-201616), calycosin (111920-201304), calycosin-7-O-β-D-glucoside (111920-201505), formononetin (111703-200603), and ononin (111703-200501) were purchased from the National institute for Food and Drug Control of China (Beijing, China). LC-MS grade methanol and acetonitrile were purchased from Merk Company (Darmstadt, Germany). HPLC grade formic acid with a purity of 99% was purchased from Anaqua chemical supply (ACS, Houston, USA). Purified water was prepared from a Milli-Q water purification system (Millipore Corporation, Bedford, MA, USA). Other chemicals (reagent grade) used were purchased from Nanjing Chemical Reagent Co, Ltd. (Nanjing, China).

Database Construction

All components of AR were obtained and cross-validated from TCMSP (http://lsp.nwu.edu.cn/tcmsp.php) database (Ru et al., 2014), ETCM (http://www.nrc.ac.cn:9090/ETCM/) (Xu et al., 2019), TCMID (http://www.megabionet.org/tcmid/) (Xue et al., 2012), CNKI (https://www.cnki.net/), PubMed (https://www.ncbi.nlm.nih.gov/pubmed), and SciFinder (https://scifinder.cas.org), and saved in SDF and Canonical SMILES structure format. All targets related to components of AR were collected from several databases, including PharmMapper (http://www.lilab-ecust.cn/pharmmapper/) (Wang et al., 2017), similarity ensemble approach (SEA, http://sea.bkslab.org/) (Gu and Lai, 2020), and Swiss Institute of Bioinformatics (SIB, http://www.swisstargetprediction.ch/) (Gfeller et al., 2014), and were limited to homo sapiens. All obtained targets were retrieved from GeneCards (http://www.genecards.org/) (Fishilevich et al., 2016) and Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/cjttd) (Li et al., 2018) to explore their function to confirm if related to lung cancer, as only targets related to lung cancer can be used in subsequent studies, and named as potential targets. All components related to lung cancer were obtained by matching targets related to lung cancer with components of AR, and named as potential effective components.

Network Construction

The potential target-effective component network was constructed using Cytoscape software (version 3.6.1). In order to further explain the mechanism of AR in the treatment of lung cancer, the protein–protein interaction (PPI) network of lung cancer–related targets was explored by STRING (version 10.5, https://string-db.org/), and was visualized with Cytoscape software (version 3.6.1). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of potential targets were performed using the plugin ClueGo (version 2.5.4) from Cytoscape software (version 3.6.1). The signal pathways closely related to lung cancer were statistically analyzed, and those with p < 0.01 after Benjamin's correction were considered to be significantly changed and selected for further research, named as potential signal pathways. Then, the potential signal pathways were evaluated by occurrence frequency of potential targets.

Preparation of Astragali Radix Sample and Component Characterization

AR sample was gained by reflux extraction twice with ten times (w/v) 70% ethanol (v/v) in thermostatic water bath for 1.5 h. The two parts of extracts were combined, and the solvent was removed by rotary evaporation to obtain dried powder of AR. The dried powder of AR was stored in 4 °C refrigerator before use. The AR sample was analyzed by ultra-performance liquid chromatography–electrospray quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) to characterize chemical component, and main signals in chromatograph were identified, and compared with the reference substances. Eight components, including calycosin-7-O-β-D-glucoside, ononin, calycosin, formononetin, astragaloside IV, astragaloside II, astragaloside I, and cycloastragenol, were accurately identified. The component information and typical total ion chromatogram (AR and reference substances) were shown in Supplementary Material S1.

Cigarettes Extract Preparation

A vacuum pump was used to simulate the human lung; a cigarette with the filter (containing 11 mg tar and 1.1 mg nicotine) was ignited and the end of the cigarette attached to a rubber hose. Smoke emitted from the burnt cigarette was dissolved in the serum-free culture medium through a glass pipette tip by a vacuum pump (Supplementary Figure S1). The smoke-solubilized serum-free culture medium was filtered by 0.22 μm sterile microporous membrane to obtain CSE.

Animals and Experiment Design

Forty male A/J mice, weighing 18–20 g, were purchased from Shanghai Experimental Animal Research Center (License number SCKK (HU) 2013-0056, Shanghai, China) and housed under pathogen-free environment with a 12h/12 h light–dark cycle and fed with food and water ad libitum. All animal experiments were conducted in accordance with the guidelines of the laboratory animals and approved by the Animal Ethics Committee of Nanjing University of Chinese Medicine.

All the mice were randomly assigned to five groups: control group, model group, DDP group, 5.2 g/kg AR group, and 2.6 g/kg AR group. Except for the control group, the lung cancer model of several groups were created by intraperitoneally injecting with benzopyrene (100 mg/kg body weight dissolved in corn oil) twice a week for 4 weeks; the DDP group were intraperitoneally injected with DDP; mice in the 5.2 g/kg AR group and 2.6 g/kg AR group were orally administrated with AR at the dose of 5.2 g/kg/d and 2.6 g/kg/d (dose conversion according to the Chinese pharmacopoeia 2020 edition part one), respectively, while the control group was given normal saline solution by gavage. After that, all the groups continued to receive different treatments for 28 weeks and once a day. After 28 weeks, all mice were sacrificed, and the lungs were collected. Immediately, a portion of lung tissue was snap-froze in liquid nitrogen and stored at −70 °C for further analysis, and another portion was fixed in 4% paraformaldehyde for histopathological study.

Histopathological Study

The lung tissues were fixed in 4% paraformaldehyde for 24 h, dehydrated and paraffin-embedded. The paraffin-embedded lung tissues were sectioned and stained with hematoxylin-eosin (HE) and immunohistochemistry (IHC). For IHC analysis, the paraffin-embedded lung tissue sections were deparaffinized in xylene and rehydrated through graded alcohol. Then, 3% H2O2 was added to block endogenous peroxidase activity. Finally, sections were blocked with normal goat serum for 30 min at room temperature and then incubated with anti-p-Bcl-2 and anti-p53 antibodies at 4 °C overnight. Sections were counterstained with hematoxylin and observed under light microscopy (Olympus, Tokyo, Japan) using ×400 magnification.

NHBE Cell Culture and Treatments

Primary normal human bronchial epithelial (NHBE) cells were purchased from Beina Chuanglian Biotechnology Co., Ltd. (Beijing, China). NHBE cells were seeded into a plastic culture flask containing DMEM, and then placed in a humidified incubator containing 5% CO2 at 37 °C. Culture medium was changed every two days, until NHBE cells reached 90% confluence. NHBE cells were digested by 0.25% trypsin and 0.02% EDTA solution, and prepared for the experiment with a density of 1×106 cells/mL. An MTT assay was used to assess the viability of NHBE cells exposed to different concentrations of CSE and AR (Supplementary Figure S2). According to the screening results, 10% CSE was chosen as the modeling concentration, and 1000 μg/ml and 500 μg/ml were chosen as the AR administration concentration. NHBE cells were divided into five groups (six wells per group): control groups (no treatment), model group (10% CSE), DDP groups (10% CSE+10 µg/ml DDP), 1000 µg/ml AR group (10% CSE + 1000 µg/ml AR), and 500 µg/ml AR group (10% CSE + 500 µg/ml AR). All cells were cultured in an incubator at 37 °C with 5% CO2 for 24 h.

Transmission Electron Microscope Observation

NHBE cells were digested with 0.25% trypsin to prepare single-cell suspension, centrifuged at 1000 rpm for 10 min, washed twice with prechilled PBS, and then fixed with prechilled 2.5% glutaric acid for 90 min at 4 °C. After washing in PBS, the cells were fixed with 1% osmium tetroxide at 4 °C for 30 min. After fixing, the cells were dehydrated with gradient ethanol and acetone, and then embedded in Epon812 resin (Sigma). The embedded blocks were cut into ultrathin sections using an ultramicrotome, and stained with uranyl acetate and lead citrate for ultrastructural examination under transmission electron microscopy (JEOL, Tokyo, Japan).

Western Blot Analysis

The NHBE cells were collected and used for Western blot analysis. The protein was extracted on ice using NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0). Lysates were centrifuged at 13,000 rpm for 10 min at 4 °C, and the supernatants were collected. Protein concentration was measured by using the DC protein assay (Bio-Rad). The separated protein samples were separated by SDS-polyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride membrane (Millipore Corporation, Billerica, MA, USA). Membranes was blocked with 5% nonfat dry milk in Tris-buffered saline with 0.05% Tween-20 (TBST) buffer, and then incubated with primary antibodies against p53 (1:500), p-Bcl-2 (diluted: 1:1000), Beclin 1 (diluted: 1:1000), AMPK (diluted: 1:1000), mTOR (diluted: 1:1000), and GAPDH (1:10,000) overnight at 4 °C. Subsequently, the membranes were incubated for 2 h at room temperature with secondary antibodies (1:10,000). Finally, the antigen–antibody complexes were visualized using enhanced chemiluminescence (Amersham) according to the manufacturer’s instructions, and visualized using Azure c600 imaging system (Azure Biosystems, Dublin, CA, USA). The protein levels were expressed as relative integrated intensity and were normalized to that of GAPDH.

Immunofluorescence Staining

The NHBE cells were washed three times with cold PBS and fixed by 4% paraformaldehyde for 15 min at room temperature, followed by permeabilization process with 1% Triton X-100 (Fisher). NHBE cells were subsequently immuno-stained with primary antibody for 2 h at room temperature and followed by fluorescein isothiocyanate-labeled secondary antibodies for 30 min at room temperature. The samples were washed twice, adhered onto coverslips, and mounted with 4’,6-diamidino-2-phenylindole–containing mounting medium. Acquisition of images was performed using a fluorescence microscope (Leica Microsystems, Wetzlar, Germany).

Real-Time PCR

Total RNA was extracted using the Trizol reagent (Invitrogen) according to the manufacturer's instructions. The RNA concentrations were determined using a spectrophotometer (ThermoFisher, Waltham, MA, USA). cDNA was synthesized from RNA (2 μg) using First-strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCR analyses were conducted to quantitate p-53, p-Bcl-2, Beclin1, AMPK, and mTOR relative expression using SYBR Green real-time PCR kit (TaKaRa, Dalian, China) with GAPDH as an internal control. The cycle threshold values from all quantitative real-time PCR experiments were analyzed using 2-ΔΔCT method, and were automatically determined by the ABI 7500 Real-Time PCR System (Applied Biosystems, USA). The primers used for real-time PCR analysis were as follow: p-53, forward primer 5′-CAG​ACA​GGC​TTT​GCA​GAA​TG-3′, reverse primer 5′-GAC​CCT​GGC​ACC​TAC​AAT​GA-3’; p-Bcl-2, forward primer 5′-AAG​CTG​TCA​CAG​AGG​GGC​TA-3′, reverse primer: 5′-CAGGCTGGA AGGAGAAGATG-3’; Beclin1, forward primer 5′-GTC​CAC​GCT​CGA​CCT​TCT​TAC-3′, reverse primer 5′-CAC​TTG​CCA​GTC​TTA​ACC​TCT​G-3’; AMPK, forward primer 5′-TGC​GTG​TAC​GAA​GGA​AGA​ATC​C-3′, reverse primer 5′-TGT​GAC​TTC​CAG​GTC​TTG​GAG​TT-3′; mTOR, forward primer 5′-CAG​TTC​GCC​AGT​GGA​CTG​AAG-3′, reverse primer 5′-GCT​GGT​CAT​AGA​AGC​GAG​AC-3′; and GAPDH, forward primer 5′-AGG​TCG​GTG​TGA​ACG​GAT​TTG-3′, reverse primer 5′-TGT​AGA​CCA​TGT​AGT​TGA​GGT​CA-3′.

Metabolism in vitro of Rat Intestinal Flora

Preparation of Anerobic Culture Medium

CaCl2 (0.2 g) and MgSO4.7H2O (0.2 g) were dissolved on 800 ml of distilled water. After that, K2HPO4·3H2O (1.0 g), KH2PO4 (1.0 g), NaHCO3 (10.0 g), NaCl (2.0 g), and resazurin solution (10 ml, 2.0 g resazurin dissolved in 10 ml double-distilled water) were added and stirred until dissolving, and then boiled distilled water was added to 1000 ml, mixed well, and cooled to room temperature. Then, tryptone (10.0 g), yeast extract (10.0 g), L-cysteine (1.0 g), and heme chloride solution (10 ml, 0.05 g heme chloride dissolved in 100 ml of 0.01 N NaOH solution) were supplemented. The pH was adjusted to 7.3 with NaOH test solution. All solution was autoclaved at 121 °C for 20 min and stored at 4 °C after cooling.

Preparation of Intestinal Flora Culture Solution

Six male Sprague–Dawley (SD) rats were provided by Shanghai Laboratory Animal Center (License No. SYXK (HU) 2013-0056, Shanghai China). Fresh intestinal contents (5.0 g) taken from SD rats were placed in a sterilized penicillin vial and mixed with normal saline at a ratio of 1 g:4 ml to make a suspension, and then the filtrate and anaerobic culture solution were mixed in a ratio of 1:9 to obtain enteric bacteria culture solution.

Sample Preparation

AR (1 mg/ml, 200 μL) was added to intestinal flora culture medium (1 ml), which was then filled with nitrogen without oxygen. The reactions were terminated by adding 1 ml n-butanol and 1 ml ethyl acetate after incubation for 0, 4, 8, 12, 24, 48, and 72 h, respectively. Next, the mixtures were vortexed for 5 min after adding 10 μL internal standard solution (nitrendipine, 2 μg/ml) and centrifuged at 14,000 rpm for 5 min. Subsequently, the organic phases were collected and evaporated under nitrogen gas, and 200 μL of methanol was added, vortexed, and centrifuged again at 14,000 rpm for 5 min, respectively. The supernatant was passed through the 0.22 μm millipore filter before injecting into the UPLC-Q-TOF-MS.

Cell Membrane Immobilized Chromatography

A549 cells were purchased from Nanjing Kaiji biology Co., Ltd (Nanjing, China). A549 cells were seeded in a plastic culture flask containing DMEM, and then placed in a humidified incubator containing 5% CO2 at 37 °C. The medium was replaced every day until A549 cells grew to 80–90% confluence. A549 cells were starved in serum-free medium for 3 h after washing with PBS. AR sample was incubated on intestinal bacteria (2 × 10−4 g/ml) for 0, 4, 8, 12, 24, 48, and 72 h, and then the incubated solution was separately added into the A549 cells for 90 min, and was washed repeatedly with PBS until without detected component. The dissociation solution (10.95 g/L Na2HPO4 and 12.91 g/L citric acid aqueous solution) was immediately added into the treated A549 cells, which were incubated at 37 °C and 5% CO2 for 30 min to inactivate the cell effect target. Finally, the dissociation solution was collected.

A549 cells were digested with pancreatin and suspended into DMEM/high glucose medium. The cell suspension was centrifuged at 3,000 rpm for 2 min at 4 °C; the cell density (1 × 107 cells/mL) was adjusted by PBS and then dissociated at room temperature for 1 h with dissociation solution. The cells were quickly placed at −80 °C for 20 min, and thawed in a thermostatic water bath at 37 °C for 10 min. The freezing–thawing process was repeated for 4 times and centrifuged at 2000 rpm for 20 min. Then, the dissociation solution and intracellular dissociation solution were collected and evaporated under nitrogen gas, and 200 μL of methanol was added, vortexed for 2 min, and centrifuged at 11,000 rpm for 10 min. Finally, the supernatant was passed through the 0.22 μm millipore filter before injecting into the UPLC-Q-TOF-MS.

UPLC-Q-TOF-MS Analysis

Chromatographic analysis was performed on a LC-20AD UPLC system (Shimadzu Corporation, Kyoto, Japan) equipped with hybrid quadrupole time-of-flight tandem mass spectrometry (Triple TOF™ 5,600, AB SCIEX, Foster City, CA, USA) coupled with electrospray ionization (ESI) source. Chromatographic separation was performed on a ACQUITY UPLC HSS T3 column (50 mm × 2.1 mm, 1.8 μm). The flow rate was 0.3 ml/min, and the mobile phase consisted of solvent A (0.1% formic acid in water, v/v) and solvent B (acetonitrile) with the optimized gradient elution: 0∼2 min, 2%∼8% B; 2∼8 min, 8%∼20% B; 8∼12 min, 20%∼35% B; 12∼18 min, 35%∼60% B; 18∼24 min, 60%∼70% B; 24∼28 min, 70%∼80% B; 28∼28 min, 80%∼2% B; and 28∼30 min, 2%∼2% B. The column temperature was set at 30 °C. In order to get better analysis results, the mass spectrometer was conducted in electrospray and multiple reaction monitoring scanning mode, in negative ion modes. The optimized parameters for mass spectrometer were as follows: capillary voltage, 0.5 kV; ion source temperature, 100 °C; cone gas flow rate, 50 L/h; desolvation temperature, 400 °C; and desolvation gas flow, 800 L/h. The information-dependent acquisition techniques and dynamic background subtraction were used to reduce the impact of matrix interference.

Statistical Analysis

All data are presented as the mean ± standard deviation. Data from mice and NHBE cells were statistically evaluated using t-test for pair-wise comparison. p < 0.05 was considered to be a significant difference, p < 0.01 was considered to be extremely significant difference, and p > 0.05 was considered to be no significant difference. All statistical analyses were performed using SPSS software (version 22.0, IBM, Chicago, IL, USA).

Results

Network Pharmacology Analysis of AR in the Treatment of Lung Cancer

Potential Targets and Components Prediction

In this study, the computer virtual screening technology was used to provide a fast and efficient approach to obtain potential targets. At length, 160 potential targets of AR in the treatment of lung cancer were obtained, and the information of potential targets (degree ≥5) are listed in Table 1. As shown in Figure 1A, the PPI network consisted of 160 nodes and 3,720 edges (average node degree of 46.5 and average local clustering coefficient of 0.634), and the node represents the potential target; the “degree” value that indicated the strength of the potential target showed the larger the node, the brighter the color, and the larger the value. The results showed that the nodes of TP53, AKT1, VEGFA, EGFR, MAPK3, CCND1, HRAS, CASP3, SRC, ALB, JUN, STAT3, HSP90AA1, IL6, MAPK1, ESR1, ERBB2, TNF, MAPK8, MTOR, FGF2, and MMP9 are larger and brighter, indicating that they play a major role in the treatment of lung cancer. Further analysis found that these potential targets are mainly related to autophagy, apoptosis, and immune-mediated, cell cycle arrest and antioxidation. It is speculated that AR may play a role in the treatment of lung cancer through autophagy, apoptosis, and immune-mediated, cell cycle arrest and antioxidation.

TABLE 1

No.Gene NameProtein NameUniprot IDDegree
1ESR2Estrogen receptor betaQ9273120
2CDK1Cyclin-dependent kinase 1P0649319
3CDK2Cyclin-dependent kinase 2P2494118
4CYP19A1AromataseP1151118
5CATCatalaseP0404018
6ESR1Estrogen receptorP0337218
7EGFREpidermal growth factor receptorP0053317
8ARAndrogen receptorP1027516
9IL2Interleukin 2P6056816
10ABCB1ATP-dependent translocase ABCB1P0818315
11HSP90AA1Heat shock protein HSP 90-alphaP0790015
12PARP1Poly(ADP-Ribose) polymerase 1P0987415
13TOP1DNA topoisomerase IP1138714
14KDRVascular endothelial growth factor receptor 2P2596814
15SRCProto-oncogene tyrosine-protein kinase SrcP1293114
16ABCG2ATP-binding cassette sub-family G member 2Q9UNQ014
17MAPK14Mitogen-activated protein kinase 14Q1653913
18MMP272 kDa type IV collagenaseP0825313
19METHepatocyte growth factor receptorP0858112
20ALOX5Arachidonate 5-lipoxygenaseP0991712
21MMP3Stromelysin-1P0825411
22MMP9Matrix metalloproteinase 9P1478011
23TYMSThymidylate synthaseP0481811
24IGF1RInsulin-like growth factor I receptorP0806911
25TERTTelomerase reverse transcriptaseO1474611
26CYP1B1Cytochrome P450 1B1Q1667811
27CHEK1Serine/threonine-protein kinase Chk1O1475710
28MCL1Induced myeloid leukemia cell differentiation protein Mcl-1Q0782010
29PIK3CGPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformP4873610
30PRKCAProtein kinase C alpha typeP1725210
31PTGS2Prostaglandin G/H synthase 2P3535410
32F2ProthrombinP0073410
33MMP1Interstitial collagenaseP039569
34ABL1Tyrosine-protein kinase ABL1P005199
35ALKALK tyrosine kinase receptorQ9UM739
36FGF2Fibroblast growth factor 2P090389
37STAT3Signal transducer and activator of transcription 3P407639
38VDRVitamin D3 receptorP114739
39VEGFAVascular endothelial growth factor AP156929
40AKT1RAC-alpha serine/threonine-protein kinaseP317499
41MTORSerine/threonine-protein kinase mTORP423458
42PIK3CAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformP423368
43PLK1Serine/threonine-protein kinase PLK1P533508
44HMOX1Heme oxygenase 1P096018
45CYP2D6Cytochrome P450 2D6P106358
46PPARGPeroxisome proliferator activated receptor gammaP372318
47CDK6Cyclin-dependent kinase 6Q005348
48ABCC1Multidrug resistance-associated protein 1P335278
49AURKAAurora kinase AO149657
50LGALS3Galectin-3P179317
51PLGPlasminogenP007477
52MPOMyeloperoxidaseP051647
53PIK3CBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformP423386
54CASP3Caspase-3P425746
55PIK3R1Phosphatidylinositol 3-kinase regulatory subunit alphaP279866
56SLC2A1Solute carrier family 2, facilitated glucose transporter member 1P111666
57BCL2L1Bcl-2-like protein 1Q078176
58NTRK1High affinity nerve growth factor receptorP046296
59ADRB2Beta-2 adrenergic receptorP075506
60TLR9Toll-like receptor 9Q9NR966
61TNFTumor necrosis factorP013756
62HDAC1Histone deacetylase 1Q135475
63BADBcl2-associated agonist of cell deathQ929345
64MMP7Matrix metalloproteinase 7P092375
65TYMPThymidine phosphorylaseP199715
66JAK2Tyrosine-protein kinase JAK2O606745
67ITGB1Integrin beta-1P055565
68CDK4Cyclin-dependent kinase 4P118025
69MDM2E3 ubiquitin-protein ligase Mdm2Q009875
70TOP2ADNA topoisomerase 2 alphaP113885
71PGRProgesterone receptorP064015
72BRAFSerine/threonine-protein kinase B-rafP150565
73PTK2Focal adhesion kinase 1Q053975
74AHRAryl hydrocarbon receptorP358695
75DAPK1Death-associated protein kinase 1P533555

Information of potential targets of AR in the treatment of lung cancer (degree ≥ 5).

FIGURE 1

Based on the acquisition of potential targets, 36 potential effective components were obtained by matching potential targets, and their information is listed in Table 2. Potential target-effective component network was constructed by Cytoscape 3.6.1 software. As shown in Figure 1B, these 160 potential targets were associated with 36 potential effective components, and the blue nodes and rose red nodes represent 160 potential targets and 36 potential effective components, respectively. Potential target-effective component network indicated that the same component could act on multiple targets, and each target is usually associated with multiple components. These results suggested that different components in AR could regulate these same or similar targets to exert effect. So, in the study of TCM, as a complex system with multiple components and multiple targets, synergistic or antagonistic interactions among the different components of TCM should be considered.

TABLE 2

NameMolecular formulaCASDegreeProtein targets from effective components
JaranolC17H14O63301-49-342ABCB1, ABCC1, ABCG2, ACTC1, AHR, AKT1, ALK, ALOX5, APEX1, AR, CAT, CDK1, CDK2, CDK6, CYP19A1, P1B1, DAPK1, EGFR, ESR1, ESR2, F2, IGF1R, KDR, KIT, MCL1, MET, MMP2, MMP3, MMP9, MYLK, NOS2, ODC1, ARP1, PIK3CG, PIK3R1, PLG, PLK1, PTGS2, PTK2, SRC, TERT, TOP2A
FlavaxinC17H20N4O683-88-538ABCG2, ABL1, ALK, ATM, AURKA, BMPR1A, BRAF, CDK1, CDK2, CDK4, CHEK1, EGFR, EPHB4, F2, HSP90AA1, JAK2, JAK3, JUN, KDR, MAPK1, MAPK14, MAPK8, MMP2, MMP3, MMP9, MTOR, NQO1, NTRK1, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PPARG, PRKCA, PTK2, SRC, TGFBR1, TLR4
Astragaloside IVC41H68O1484687-43-437ADRB2, AKT1, AKT2, AR, CAT, CDK1, CDK4, CYP2D6, EGFR, ESR1, F2, FGF2, HMOX1, HSP90AA1, IGF1R, IKBKB, IL2, ITGA2B, ITGAV, ITGB1, LGALS3, MDM2, MET, MMP1, MTOR, NRP1, PARP1, PIK3CA, PIK3CG, PLG, PKCA, SRC, STAT3, TOP1, TYMS, VDR, VEGFA
IsorhamnetinC16H12O7480-19-337ABCB1, ABCC1, ABCG2, AHR, AKT1, ALK, ALOX5, APEX1, CAT, CDK1, CDK2, CDK6, CYP19A1, CYP1B1, DAPK1, EGFR, ESR1, ESR2, F2, HMOX1, IGF1R, KDR, MET, MMP2, MMP3, MMP9, MPO, MYLK, PARP1, PIK3CG, PIK3R1, PLG, PLK1, PTK2, SRC, TERT, TOP2A
RhamnocitrinC16H12O6569-92-637ABCB1, ABCC1, ABCG2, ADA, AHR, ALK, ALOX5, APEX1, AR, CAT, CDK1, CDK2, CDK6, CFTR, CYP19A1, CYP1B1, DAPK1, EGFR, ESR1, ESR2, F2, GSTM1, IGF1R, KDR, MCL1, MET, MMP2, MMP3, MMP9, MPO, PIK3CG, PI3R1, PLG, PLK1, PTGS2, SRC, TERT
KaempferolC15H10O6520-18-335ABCB1, ABCC1, ABCG2, ADA, AHR, ALK, ALOX5, CAT, CDK1, CDK2, CDK6, CFTR, CYP19A1, CYP1B1, DAPK1, EGFR, ESR1, ESR2, F2, IGF1R, KDR, MET, MMP2, MMP3, MMP9, MPO, PARP1, PIK3R1, PLK1, PTGS2, PTK2, SRC, TERT, TOP1, VEGFA
QuercetinC15H10O7117-39-535ABCB1, ABCC1, ABCG2, AHR, AKT1, ALK, ALOX5, APEX1, CALR, CDK1, CDK2, CDK6, CYP19A1, CYP1B1, DAPK1, EGFR, ESR2, F2, IGF1R, KDR, MET, MMP2, MMP3, MMP9, MPO, MYLK, PARP1, PIK3CG, PIK3R1, PLK1, PTK2, SRC, TERT, TOP1, TOP2A
Astrachrysoside AC47H78O18123914-38-533AR, CAT, CDK1, CDK2, CTSB, CYP2D6, ELANE, ESR1, FGF2, FGF2, FGFR2, HMOX1, HSP90AA1, IKBKB, IL2, ITGA2B, ITGAV, ITGB1, LGALS3, MAPK14, MET, MMP2, MMP9, MTOR, NTRK1, PIK3CA, PIK3CB, PPARG, SLC2A1, STAT3, TYMS, VDR, VEGFA
Astrapterocarpan glucosideC23H26O1094367-42-732ABL1, AR, CASP3, CASP8, CAT, CDK1, CDK2, CHEK1, CYP19A1, EGFR, ERBB2, HMOX1, HSPA5, IL2, LGALS3, MAP2K1, MAPK1, MAPK14, MCL1, MGMT, MMP1, MMP2, MMP3, MMP9, ODC1, PARP1, PDGFRB, PTGS2, PTPN11, SLC2A1, TOP1, TYMP
IsomucronulatolC45H72O1684676-88-030ABL1, ALK, AURKA, BAD, CASP3, CCND1, CDK1, CDK2, CHEK1, CYP19A1, EGFR, EP300, EZR, FLT1, HDAC9, HSP90AA1, KDR, MAPK1, MET, MMP1, MMP7, MTOR, PIK3CB, PIK3CG, PIK3R1, PLK1, PRKCA, RAF1, RET, SRC
CalycosinC16H12O520575-57-930ABCB1, ABCC1, ABCG2, ALK, ALOX5, BAD, BCL2, CDK2, CDK6, CHEK1, CYP19A1, CYP1B1, EGFR, ESR1, ESR2, F2, IGF1R, IGFBP3, IL2, KDR, MCL1, MET, PARP1, PLAU, PLAUR, PLG, PLK1, TERT, TLR9, TNF
CycloastragenolC30H50O584605-18-529AKT1, AKT2, AKT3, ALOX5, AR, ATR, AURKA, BRAF, CDK2, CHEK1, EGFR, EPHX2, ERBB2, ESR1, ESR2, FGFR1, IGF1R, IKBKB, JAK2, KDR, MAPK14, MAPK3, MAPK8, MDM2, MMP3, MTOR, PGR, PLK1, ROS1
FormononetinC16H12O4485-72-327ABCB1, ABCG2, AR, BAD, BCL2, CAT, CHEK1, CYP19A1, CYP1B1, EGFR, ERBB2, ERBB3, ERBB4, ERCC5, ESR1, ESR2, EZR, IDH1, IL2, MCL1, MMP2, MMP9, PPARG, RAF1, SRC, TLR9, TOP1
LariciresinolC20H24O627003-73-227ABL1, ADA, AKT2, ALOX5, AURKA, BRAF, CDK1, CDK2, CDK4, CFTR, CHEK1, EPHB4, HDAC1, HIF1A, JAK2, MAP2K1, MCL1, MMP7, MTOR, NTRK1, PIK3CA, PIK3CB, PIK3CG, SLC2A1, TLR4, TOP1, XIAP
OnoninC22H22O9486-62-427ABL1, ACE, CASP3, CD274, CYP19A1, EGFR, HDAC1, HRAS, IL2, KIT, MAPK14, MGMT, MMP1, MMP2, MMP3, MMP7, MMP9, NRAS, NTRK1, PARP1, PDGFRA, PPARG, PRKCA, SRC, TNF, TOP1, TYMP
Biochanin AC16H12O5491-80-526ABCB1, ABCC1, ABCG2, ADRB2, BAD, BCL2, BRAF, CCND1, CHEK1, CHEK2, COMT, CYP19A1, CYP1B1, EGFR, ESR1, ESR2, HSP90AA1, IGFBP3, IL2, MCL1, NTRK1, PLAU, PPARG, RAF1, TERT, TLR9
AlexandrinC35H60O6474-58-825ABL1, AKT1, ALK, ALOX5, AURKA, BCL2L1, FASN, FGF2, FGFR1, FLT1, HDAC1, HSP90AA1, IGF1R, IL2, JAK2, KIT, MAPK14, MET, PDGFRA, PDGFRB, PTPN11, RET, STAT3, TYMS, VEGFA
AstraisoflavaninC23H28O10131749-60-525ABL1, BCL2L1, CASP3, CAT, CD274, CDK1, CDK2, CHEK1, ESR1, ESR2, GSTM1, HMOX1, HRAS, HSP90AA1, IGFBP3, MAPK8, MMP1, MMP7, PARP1, PIK3CA, PTGS2, SLC2A1, TOP2A, TYMP, TYMS
Betulinic acidC30H48O3472-15-125ACE, AR, CAT, CYP17A1, CYP19A1, EDNRA, ESR2, IKBKB, ITGB1, MDM2, MMP1, MMP2, MMP3, NOS2, PGR, PPARG, PTGS2, PTPN11, RARA, RARB, TERT, TLR9, TOP1, TOP2A, VDR
DaidzeinC15H10O4486-66-825ABCB1, ABCC1, ABCG2, AR, BAD, BRAF, CAT, CDK6, CFTR, CYP19A1, CYP1B1, EGFR, ESR1, ESR2, HSP90AA1, IGFBP3, IL2, MCL1, NTRK1, PARP1, PLAU, PPARG, PTGS2, RAF1, TLR9
Soyasaponin IC48H78O1851330-27-925ADRB2, AR, BCL2L1, CASP3, CASP9, CAT, CYP2D6, EDNRA, ESR2, F2, GLI1, GRB2, HLA-A, HMOX1, IGF1R, IL2, ITGB1, JUN, KDR, MMP9, PARP1, SRC, STAT3, TYMS,VDR
GenistinC21H20O10529-59-924ABCB1, ABCG2, ALB, CDK2, CYP19A1, EGFR, ESR1, ESR2, HRAS, HSP90AA1, IL2, MAPK14, MGMT, MMP1, MMP2, MMP7, NRP1, PRKCA, PTGS2, SLC2A1, SRC, TNF, TOP1, TYMP
Astragaloside IIC43H70O1584676-89-123ABCB1, ADRB2, BCL2L1, CDK1, CDK2, CDK4, CTSB, CYP2D6, EGFR, F2, FGF2, HSP90AA1, KDR, LGALS3, MAPK14, MET, PPARG, PRKCA, STAT3, TOP1, TYMS, VDR,VEGFA
IsoflavanoneC15H12O24737-27-323ABCG2, ACE, AURKA, CASP3, CAT, CDK1, CDK2, CREBBP, CTSB, CYP19A1, DNMT3A, ELANE, EP300, ESR1, ESR2, HMOX1, MAPK14, MCL1, MPO, PGR, PIK3CA, PIK3CB, TLR9
Astragaloside ⅢC41H68O1484687-42-322ADRB2, AKT1, AR, CAT, CDK1, CDK2, CDK4, CDK6, CYP2D6, ESR1, ESR2, FGF2, FGFR1, HSP90AA1, IL2, KDR, LGALS3, RARB, STAT3, TYMS, VDR, VEGFA
Astrasieversianin XVC46H76O17101843-83-820ADRB2, AKT1, AKT2, CDK1, CYP2D6, FGF2, FGFR1, HDAC1, HLA-A, HSP90AA1, IL2, MAPK14, MTOR, PIK3CA, PIK3CG, SLC2A1, STAT3, TOP1, TYMS, VEGFA
HederageninC30H48O4465-99-620ALOX5, AR, CYP17A1, CYP19A1, EDNRA, EDNRB, ESR1, ESR2, IL6, ITGB1, MAPK3, MDM2, MMP1, MMP2, MMP3, NOS2, PGR, PTPN11, TERT, TOP1
SyringaresinolC22H26O821453-69-019ABCB1, AURKA, CDK1, CDK2, CHEK1, ERBB2, HDAC1, HDAC9, HIF1A, MCL1, MMP1, MTOR, NOS2, PCNA, PIK3CA, PIK3CB, PIK3CG, SERPINE1, TOP1
Acetylastragaloside IC47H74O1784687-47-817ABCB1, AR, BCL2L1, CAT, CDK1, CYP2D6, ESR2, FGF2, HMOX1, HSP90AA1, LGALS3, PARP1, PRKCA, STAT3, TYMS, VDR, VEGFA
LupeolC30H50O545-47-116ABL1, AR, BIRC5, CYP17A1, CYP19A1, ESR1, ESR2, IGF1R, JAK2, KDR, MAPK14, MDM2, MPO, PRKCA, SHH, VDR
Calycosin-7-O-β-D-glucosideC22H22O1020633-67-414ABCB1, ABL1, HRAS, HSP90AA1, IL2, MAPK14, MET, MGMT, PRKCA, SRC, TNF, TOP1, TYMP, TYMS
RutinC27H30O16153-18-414ABCG2, ACTC1, ALOX5, AR, CAT, CYP1B1, ESR2, IL2, PARP1, PLG, PTGS2, TERT, TNF, TP53
Astragaloside IC43H68O1684680-75-112ABCB1, AR, BCL2L1, CAT, CDK1, CYP2D6, ESR2, FGF2, HMOX1, HSP90AA1, LGALS3, PARP1, PRKCA, STAT3, TYMS, VDR, VEGFA
HirsutrinC21H20O12482-35-912ABCG2, ALOX5, CAT, CYP1B1, ESR1, IL2, PARP1, PLG, PTGS2, SRC, TERT, TNF
LupenoneC30H48O1617-70-512AKT1, AR, CAT, CYP17A1, CYP19A1, EPHB4, HPGD, KDRMAPK14, MPO, PDGFRB, PGR
CoumarinC9H6O291-64-52PARP1, TYMS

The summary of potential effective components of AR in the treatment of lung cancer.

TABLE 3

Potential targets-signal pathwayGenes/ Term%Nr. GenesPotential target-signal pathwayGenes/Term%Nr. Genes
Pathways in cancer16.0485Progesterone-mediated oocyte maturation20.2020
PI3K-Akt signaling pathway15.2554Transcriptional misregulation in cancer10.7520
Proteoglycans in cancer23.3847Endometrial cancer34.4820
Human papillomavirus infection12.1240Bladder cancer48.7820
Hepatitis B23.9339Sphingolipid signaling pathway15.9719
MicroRNAs in cancer13.0439mTOR signaling pathway12.4219
Human cytomegalovirus infection16.4437T cell receptor signaling pathway18.8119
Human T-cell leukemia virus 1 infection16.8937Insulin signaling pathway13.8719
Prostate cancer38.1437p53 signaling pathway25.0018
MAPK signaling pathway12.2036Axon guidance9.9418
Kaposi sarcoma–associated herpesvirus infection19.3536Toll-like receptor signaling pathway17.3118
Focal adhesion17.5935Fc epsilon RI signaling pathway26.4718
Ras signaling pathway14.2233Measles13.6418
Human immunodeficiency virus 1 infection15.5733Cell cycle13.7117
Rap1 signaling pathway14.5630Osteoclast differentiation13.2817
FoxO signaling pathway22.7330Th17 cell differentiation15.8917
Apoptosis22.0630Apelin signaling pathway11.6816
Cellular senescence18.7530Natural killer cell mediated cytotoxicity12.2116
Hepatocellular carcinoma17.8630Herpes simplex virus 1 infection8.6516
Breast cancer19.7329Platelet activation12.1015
Gastric cancer19.4629NOD-like receptor signaling pathway8.4315
Viral carcinogenesis13.9328IL-17 signaling pathway16.1315
HIF-1 signaling pathway27.0027B cell receptor signaling pathway21.1315
Thyroid hormone signaling pathway23.2827Cholinergic synapse13.3915
Hepatitis C17.4227GnRH signaling pathway15.0514
Epstein-Barr virus infection13.4327Oxytocin signaling pathway9.1514
Non-small cell lung cancer40.9127Insulin resistance12.9614
Central carbon metabolism in cancer41.5427cGMP-PKG signaling pathway7.8313
ErbB signaling pathway30.5926Longevity regulating pathway14.6113
Relaxin signaling pathway20.0026Gap junction14.7713
AGE-RAGE signaling pathway in diabetic complications26.0026Non-alcoholic fatty liver disease (NAFLD)8.7213
Colorectal cancer30.2326AMPK signaling pathway10.0012
Pancreatic cancer34.6726Longevity regulating pathway19.3512
Melanoma36.1126Serotonergic synapse10.4312
Chronic myeloid leukemia34.2126Adrenergic signaling in cardiomyocytes7.5911
Fluid shear stress and atherosclerosis18.7126Adherens junction15.2811
JAK-STAT signaling pathway15.4325Fc gamma R-mediated phagocytosis12.0911
Glioma33.3325Leukocyte transendothelial migration9.8211
Neurotrophin signaling pathway20.1724Melanogenesis10.8911
Regulation of actin cytoskeleton11.2124Adipocytokine signaling pathway15.9411
Estrogen signaling pathway17.3924Pertussis14.4711
Small cell lung cancer25.8124Thyroid cancer29.7311
C-type lectin receptor signaling pathway22.1223NF-kappa B signaling pathway10.5310
Chagas disease (American trypanosomiasis)22.3323Long-term potentiation14.9310
Toxoplasmosis20.3523Parathyroid hormone synthesis, secretion and action9.4310
Tuberculosis12.8523Leishmaniasis13.5110
Influenza A13.4523Amebiasis10.4210
Renal cell carcinoma33.3323Th1 and Th2 cell differentiation9.789
Chemokine signaling pathway11.5822Long-term depression15.009
Phospholipase D signaling pathway14.8622Type II diabetes mellitus19.579
Signaling pathways regulating pluripotency of stem cells15.8322Amyotrophic lateral sclerosis (ALS)17.659
Prolactin signaling pathway31.4322Epithelial cell signaling in Helicobacter pylori infection13.249
Acute myeloid leukemia33.3322Mitophagy12.318
Autophagy16.4121Apoptosis24.248
VEGF signaling pathway35.5921Regulation of lipolysis in adipocytes14.558
Choline metabolism in cancer21.2121Shigellosis12.318
cAMP signaling pathway9.4320Aldosterone-regulated sodium reabsorption16.226
TNF signaling pathway18.1820

Potential target-pathway enrichment of AR in the treatment of lung cancer.

Enrichment Analysis and Mechanism Prediction

Go enrichment analysis was performed on 160 potential targets, and limiting annotation was selected to homo sapiens. The top 10 terms of biological process (Figure 2A), molecular function (Figure 2B), and cell composition (Figure 2C) were selected. The results indicated that AR-regulated lung cancer mainly related to cellular process, biological regulation, response to stimulus, regulation of biological process, regulation of cellular process, and metabolic process, and mainly involved binding, protein binding, and catalytic activity in molecular function, and cell part, intracellular, intracellular part, cytoplasm, and intracellular organelle in cell composition.

FIGURE 2

KEGG analysis was performed using the ClueGO database in Cytoscape 3.6.1, and 115 KEGG pathways with p-value less than or equal to 0.01 were obtained (Table 3). In order to more intuitively show the relationship among potential targets and signal pathways, the potential target-signal pathway network was constructed (Figure 2D). According to the KEGG analysis, AR in the treatment of lung cancer was related to PI3K-Akt signaling pathway, MAPK signaling pathway, Ras signaling pathway, etc.

Experimental Validation of AR in the Treatment of Lung Cancer In Vivo

Body Weight Change and Overall Appearance

The body weight changes of the animals in different groups were shown in Figure 3A. Compared with the control group, the body weight of mice in other four groups were decreased, and mice in model group had the smallest body weight among these four groups (p < 0.01). Besides, compared with the model group, the body weight of 5.2 g/kg AR group and 2.6 g/kg AR group were significantly increased (p < 0.01, p < 0.05), and the most significant effect was observed in 5.2 g/kg AR group. The appearance of all mice were observations throughout the experimental period, and the results showed that the mice in model group suffered from nose bleeding and sparse neck hair, and no obvious symptoms in other four groups were observed.

FIGURE 3

Histopathological Study

After 28 weeks, lungs were removed from the mice for analysis. Except for the control group, what were observed in the other groups showed obvious lung lesions, tumor-like proliferation, and tumor nodules. Compared with the model group, the mice by DDP, 5.2 g/kg AR, and 2.6 g/kg AR treatment were able to significantly reduce (p < 0.01) the number of lung tumor nodules (Figure 3B). The HE staining and IHC staining were used to determine the success of the lung cancer model and the therapeutic effect of AR against lung cancer. As shown in Figure 3C, the HE staining results showed that lung tissues of mice in the control group had the intact structure, clear alveolar outline, thin alveolar septum, and no sign of inflammation, while the lung tissues disappear in the model group had serious damage to the alveolar structure, cancerous proliferation, and fibrosis, which indicates that the lung cancer model of A/J mice was successfully constructed. In addition, the administration of DDP and AR prevented the structural changes in the lung tissue and the infiltration of inflammatory cell, and improved lung tissue integrity. In addition, the above findings also suggest the effectiveness of AR in the treatment of lung cancer. The results of IHC staining were consistent with the HE staining results. In addition, the IHC staining results indicated that compared with the control group, the p53 expression (Figures 3D,E) was significantly decreased (p < 0.01), and the p-Bcl-2 expression (Figure 3F,G) was significantly increased (p < 0.01) in the lung tissue of model group. The administration of AR could upregulate the p53 expression and downregulate the p-Bcl-2 expression in the lung tissue, which indicated that AR can reverse the expression of p53 and p-Bcl-2 in lung cancer mice.

Potential Targets and Mechanism Validation In Vitro

Astragali Radix Treatment Inhibited Cell Autophagy Induced by CSE

CSE was used to induce autophagy in NHBE cells. The result showed that a large number of autophagy vacuoles appeared in the cytoplasm. Besides, autophagosome fuse with lysosome to form autolysosome, which decompose and destroy the organelles and damage the normal function of cells. After treatment with AR, the number of autophagosomes and autolysosomes in the cells was significantly reduced, and the structural integrity of the cells was increased, as shown in Figure 4A.

FIGURE 4

Astragali Radix on p53, p-Bcl-2 and Mammalian Target of Rapamycin Expression in NHBE Cells

The potential targets, p53, p-Bcl-2, and mTOR, predicted by network pharmacology technology, were verified at the protein and gene levels. As shown in Figures 4B,C, compared with the model group, the p53 expression in NHBE cells was significantly increased in the 1000 µg/ml AR group and 500 µg/ml AR group (p < 0.01). As shown in Figures 5A,B, immunofluorescence staining analyses showed that 1000 µg/ml AR and 500 µg/ml AR could increase the expression of p53 (p < 0.01). RT-PCR results (Figures 5E,F) showed that the relative mRNA level of cellular p53 has been increased (p < 0.01) and the relative mRNA level of nuclear p53 has been decreased (p < 0.01) by the treatment of 1000 µg/ml AR, respectively. The above results indicated that AR could promote p53 expression, thereby inhibiting autophagy and protecting cells from autophagy.

FIGURE 5

Western blot analysis (Figures 4B,D) and immunofluorescence (Figures 5A,C) showed that p-Bcl-2 expression was significantly reduced in NHBE cells after treatment with AR (p < 0.01). In addition, compared with model group, the relative mRNA level of p-Bcl-2 was significantly reduced (p < 0.01) in 1000 µg/ml AR group and 500 µg/ml AR group (Figure 5G). The above results indicated that AR could reduce the phosphorylation level of Bcl-2, inhibit autophagy, and protect cells.

As shown in Figures 4B,E, compared with the model group, mTOR expression in NHBE cells was significantly increased in the 1000 µg/ml AR group and 500 µg/ml AR group (p < 0.01). RT-PCR results (Figure 5H) showed that the relative mRNA level of mTOR has also been increased by the treatment of 1000 µg/ml AR and 500 µg/ml AR (p < 0.01). Immunofluorescence staining showed increased expression of mTOR expression in AR-treated cells at the concentration of 1000 µg/ml AR and 500 µg/ml AR (Figures 5A,D, p < 0.01). mTOR is a major negative regulator of autophagy and a key protein for controlling autophagy. The above results showed that AR could increase mTOR expression and regulate cell autophagy to protect cells.

Effect of Astragali Radix on p53/AMPK/Mammalian Target of Rapamycin Signaling Pathway

According to the KEGG analysis, AR in the treatment of lung cancer was mainly related to PI3K-Akt signaling pathway. So, the expression of molecules downstream of the PI3K-Akt signaling pathway was mainly explored. Except for p53, p-Bcl-2, and mTOR (Figures 4,5), the expression of AMPK and Beclin1 at the protein and gene levels was also determined. As shown in Figure 6, compared with model group, Western blot analysis and immunofluorescence staining showed a significant reduction (p < 0.01) on AMPK and Beclin1 expression in NHBE cells after being treated with 1000 µg/ml AR. Besides, the relative mRNA level of AMPK and Beclin1 was significantly reduced (p < 0.01) in 1000 µg/ml AR group and 500 µg/ml AR group. It has been documented that p53 mediates autophagy through an AMPK/mTOR-dependent pathway (Tasdemir et al., 2008). AMPK activation leads to autophagy through negative regulation of mTOR and that many other factors involved in the autophagic process govern autophagy through AMPK/mTOR signaling (Jing et al., 2011). Based on the above research results, we speculate that AR in the treatment of lung cancer may through p53/AMPK/mTOR signaling pathway (Figure 7), but further validation is still required.

FIGURE 6

FIGURE 7

Screening of Effective Components by Metabolism in vitro of Rat Intestinal Flora and Cell Membrane–Immobilized Chromatography

The UPLC-Q-TOF-MS analysis results indicated that these components in AR have undergone different degrees of metabolic transformation under the action of intestinal flora, and the typical total ion chromatogram of blank bacterial solution and the intestinal flora incubation solution of AR (2 h) as shown in Supplementary Figure S3. Detailed metabolite information was listed in Table 4, and the metabolic pathway mainly involves oxidation, reduction, hydrolytic deglycosylation, etc. The results of cell membrane–immobilized chromatography are shown in Figure 8. The six effective components, such as calycosin-7-O-β-D-glucoside, ononin, calycosin, astragaloside IV, metabolite of astragaloside II (M5), and cycloastragenol, can bind to cell membranes (Figure 8A). The three components, that is, reduction product of calycosin (M9), calycosin, and formononetin, can enter into the cell through the cell membrane by passive diffusion (Figure 8B).

TABLE 4

No.RT (min)Identified compoundsElement compositionIonizationPrototypeMetabolic way
111.09Astragaloside IC45H72O16[M+COOH]-
213.52Astragaloside IIC43H70O15[M+COOH]-
312.78Astragaloside IVC41H68O14[M+COOH]-
49.83CalycosinC16H12O5[M-H]-
56.04Calycosin -7-O-β-D-glucosideC22H22O10[M+COOH]-
68.72OnoninC22H22O9[M+COOH]-
713.64M1C45H68O16[M-H]-Astragaloside Idehydrogenation
813.46M2C36H60O10[M-H]-Astragaloside I/Astragaloside II/Astragaloside IVglycosylation
913.57M3C39H62O11[M+COOH]-Astragaloside Iglycosylation
1014.97M4C30H50O5[M+COOH]-Astragaloside I/Astragaloside II/Astragaloside IVglycosylation
1113.89M5C37H60O9[M+COOH]-Astragaloside IIglycosylation+dehydroxylation
1213.47M6C35H58O9[M+COOH]-Astragaloside IVglycosylation
1312.14M7C16H12O4[M-H]-Calycosin/Ononindehydroxylation
1410.68M8C16H16O5[M-H]-Calycosinhydrogenation+open loop
1512.34M9C16H16O4[M-H]-Calycosinhydrogenation+deoxidation
164.781M10C22H22O11[M+COOH]-Calycosinhydrogenation+glucuronidation

Identification of components in AR by using UPLC-ESI-Q-TOF-MS method in negative ion mode.

FIGURE 8

Ultimately, these effective components, that is, calycosin-7-O-β-D-glucoside, ononin, calycosin, astragaloside IV, astragaloside II, cycloastragenol, and formononetin, together form the material basis of AR for prevention and treatment of lung cancer, and they come from the two-type components, flavone and saponin.

Discussion

In this study, an integrated strategy for effective-component discovery of AR in the treatment of lung cancer was established. The results indicated that the integrated strategy can be applied to the efficiently screen effective components in complex systems. In our research on the bioactivity of AR, we found that the administered doses were high compared with single component drug. Therefore, the screening and confirmation of effective components in this article will help to reduce the dose by removing the ineffective components.

Modern pharmacological studies have shown that the activity of drugs is closely related to their cell membrane affinity and permeability. An important step in the role of TCM is the binding of effective components to cell membranes, specific enzymes, or receptors in cells. In this study, A549 cells were used as the separation carrier, AR was taken as the research object, and the specific affinity between each component in AR and cells was determined by cell membrane–immobilized chromatography. It is worth noting that the screening results show that calycosin-7-O-β-D-glucoside, ononin, calycosin, astragaloside IV, astragaloside II, cycloastragenol, and formononetin may be effective components of AR in the treatment of lung cancer, and which is consistent with the previous research results of AR in the prevention and treatment of cancer (He et al., 2013; Cheng et al., 2016; Xu et al., 2018). Through the ages, TCM have shown good efficacy in treating many and complex diseases (Sreenivasmurthy et al., 2017). The above research on the effective components of AR once again proved that the components of TCM are very complex and diverse, and multicomponent and multi-target may be the characteristic of TCM in treating diseases.

Autophagy has been implicated in a wide range of human diseases, including lung disorders such as lung cancer, chronic obstructive pulmonary disease, and lung infection diseases (Ryter and Choi, 2010; Ryter et al., 2012; Liu, et al., 2017; He et al., 2019). The article mainly investigated the mechanism of AR in the treatment of lung cancer from the perspective of autophagy according to the predictions of network pharmacology. The results suggested that AR may inhibit the development of lung cancer by reducing the p53 expression in the nucleus and promoting p53 expression in the cytoplasm, downregulating the level of p-Bcl-2 and promoting the autophagy inhibitory factor mTOR expression. In order to further explore the mechanism of AR in the treatment of lung cancer, except for the p53, p-Bcl-2 and mTOR, the expression of other molecules downstream of the PI3K-Akt signaling pathway was explored, including AMPK and Beclin1. Under stress, AMPK can promote the dissociation and phosphorylation of autophagy-related gene Bcl-2 (Zhou et al., 2011; He et al., 2012; Meng et al., 2015) and inhibit mTOR expression (Chen et al., 2015; Prietodomínguez et al., 2016; Yu et al., 2017), and ultimately promote the occurrence and development of autophagy. Beclin1 is an interacting protein of Bcl-2 (He et al., 2013); binding of Bcl-2 to Beclin1 inhibits Beclin1-mediated autophagy via sequestration of Beclin1 away from class III PI3K; and the interaction between Bcl-2 and Beclin1 is related to mTOR kinase-dependent phosphorylation of Bcl-2 (Levine et al., 2008; Pattingre et al., 2008; Chiang et al., 2018; Xu and Qin, 2019). The preliminary research results indicated that the regulation of autophagy may be a useful strategy in the treatment of lung cancer.

In this study, an integrated strategy for effective-component discovery of AR in the treatment of lung cancer was established, which provides a valuable reference mode for finding the effective components of TCM. In addition, preliminary research results indicated that AR in the treatment of lung cancer may through p53/AMPK/mTOR signaling pathway, which laid a foundation for further in-depth study of the mechanism of AR in lung cancer. Despite some promising results were obtained in the study, there are still several potential limitations to improve. First, we have to admit that network pharmacology virtual screening has some limitations, and the predicted effective components and potential targets may need to be further comprehensively verified through a variety of different technologies. Even though the study adopts an integrated research strategy combining network analysis and in vitro/vivo studies, it still could not avoid some false positives. Moreover, we found that the dosage of AR was very high compared with single-component drug. Therefore, it is necessary to further knock out invalid components of AR to reduce dosage. Finally, the preliminary research results indicated that AR in the treatment of lung cancer may be through p53/AMPK/mTOR signaling pathway; certainly, further experimental validation should be needed to confirm this hypothesis.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, and further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the Animal Ethics Committee of Nanjing University of Chinese Medicine.

Author contributions

BY and LF conceived the idea of the study and prepared the manuscript. NY, YC, and MZ conducted the experiments and analyzed data. YL, ZX, and BW designed the experiments and participated in the interpretation of experimental results. LF revised the manuscript. XBJ supervised the study. All authors confirmed the final manuscript.

Funding

This work was financially supported by the National Key research and development program of China (2018YFC1706900) and “Double First-Class” University project of China Pharmaceutical University (CPU2018GF07; CPU2018GY11).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.580978/full#supplementary-material

Abbreviations

AR, astragali radix; TCM, traditional Chinese medicine; DDP, cisplatin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p53, protein 53; p-Bcl-2, phosphorylated B-cell lymphoma-2; mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; PPI, protein–protein interactions; GO, gene Ontology; KEGG, kyoto encyclopedia of genes and genomes; CSE, cigarettes extract; HE, hematoxylin-eosin; IHC, immunohistochemistry; NHBE, primary normal human bronchial epithelial; UPLC-ESI-TO-MS, ultra-performance liquid chromatography–electrospray quadrupole time-of-flight mass spectrometry.

References

  • 1

    ChenY. C.ChenD.LiuS. J.YuanT. Y.GuoJ.FangL. H.et al (2019). Systematic elucidation of the mechanism of genistein against pulmonary hypertension via network pharmacology approach. Int. J. Mol. Sci20 (22), 5569. 10.3390/ijms20225569

  • 2

    ChenZ. T.ZhaoW.QuS.LiL.LuX.SuF.et al (2015). PARP-1 promotes autophagy via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells. Mol. Med. Rep12 (2), 18681876. 10.3892/mmr.2015.3604

  • 3

    ChengH.GeX.ZhuoS.GaoY.ZhuB.ZhangJ.et al (2018). β-elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2. Front. Pharmacol9, 1413. 10.3389/fphar.2018.01413

  • 4

    ChengX. D.GuJ. F.YuanJ. R.FengL.JiaX. B. (2016). Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC-α/ERK1/2 pathway: an in vitro investigation. Mol. Med. Rep13 (6), 37093710. 10.3892/mmr.2016.4976

  • 5

    ChiangW. C.WeiY.KuoY. C.WeiS.ZhouA.ZouZ.et al (2018). High-throughput screens to identify autophagy inducers that function by disrupting Beclin 1/Bcl-2 binding. ACS Chem. Biol13 (8), 22472260. 10.1021/acschembio.8b00421

  • 6

    FishilevichS.ZimmermanS.KohnA.Iny SteinT.OlenderT.KolkerE.et al (2016). Genic insights from integrated human proteomics in GeneCards. Database2016, baw030. 10.1093/database/baw030

  • 7

    GfellerD.GrosdidierA.WirthM.DainaA.MichielinO.ZoeteV. (2014). SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res42, W32W38. 10.1093/nar/gku293

  • 8

    GuS.LaiL. H. (2020). Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach. Acta Pharmacol. Sin41, 432438. 10.1038/s41401-019-0306-9

  • 9

    HeC.BassikM. C.MoresiV.SunK.WeiY.ZouZ.et al (2012). Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature481 (7382), 511515. 10.1038/nature10758

  • 10

    HeC.ZhuH.LiH.ZouM.XieZ. (2013). Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. Diabetes62 (4), 12701281. 10.2337/db12-0533

  • 11

    HeH.ZhouX.WangQ.ZhaoY. (2013). Does the couse of astragalus-containing Chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. Evid Based Complement Alternat Med, 2013, 426207. 10.1155/2013/426207

  • 12

    HeY.LiuH.JiangL.RuiB.MeiJ.XiaoH. (2019). miR-26 Induces apoptosis and inhibits autophagy in non-small cell lung cancer cells by suppressing TGF-β1-JNK signaling pathway. Front. Pharmacol9, 1509. 10.3389/fphar.2018.01509

  • 13

    JiangL.WangW.HeQ.WuY.LuZ.SunJ.et al (2017). Oleic acid induces apoptosis and autophagy in the treatment of Tongue Squamous cell carcinomas. Sci. Rep7 (1), 11277. 10.1038/s41598-017-11842-5

  • 14

    JingK.SongK. S.ShinS.KimN.JeongS.OhH. R.et al (2011). Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy7 (11), 13481358. 10.4161/auto.7.11.16658

  • 15

    KeB.WuX.YangQ.HuangY.WangF.GongY.et al (2019). Yi-qi-yang-yin-tian-sui-fang enhances cisplatin-induced tumor eradication and inhibits interleukin-7 reduction in non-small cell lung cancer. Biosci. Rep39 (6), BSR20190052. 10.1042/BSR20190052

  • 16

    LevineB.SinhaS.KroemerG. (2008). Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy4 (5), 600606. 10.4161/auto.6260

  • 17

    LiY. H.YuC. Y.LiX. X.ZhangP.TangJ.YangQ.et al (2018). Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res46 (D1), D1121D1127. 10.1093/nar/gkx1076

  • 18

    LiuG.PeiF.YangF.LiL.AminA. D.LiuS.et al (2017). Role of autophagy and apoptosis in non-small-cell lung cancer. Int. J. Mol. Sci18 (2), 367. 10.3390/ijms18020367

  • 19

    LouJ. S.YanL.BiC. W.ChanG. K.WuQ.LiuY.et al (2016). Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. Sci. Rep6 (1), 31926. 10.1038/srep31926

  • 20

    MengF. Y.NingH.SunZ. X.HuangF. F.LiY. C.ChuX.et al (2015). Ursolic acid protects hepatocytes against lipotoxicity through activating autophagy via an AMPK pathway. Journal of Functional Foods17, 172182. 10.1016/j.jff.2015.05.029

  • 21

    PattingreS.TassaA.QuX.GarutiR.LiangX. H.MizushimaN.et al (2008). Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell122 (6), 92793910.1016/j.cell.2005.07.002

  • 22

    PrietodominguezN.OrdonezR.FernandezA.GarciapalomoA.MuntaneJ.GonzalezgallegoJ.et al (2016). Modulation of autophagy by sorafenib: effects on treatment response. Front. Pharmacol7, 151. 10.3389/fphar.2016.00151

  • 23

    RuJ.LiP.WangJ.ZhouW.LiB.HuangC.et al (2014). TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminf6 (1), 13. 10.1186/1758-2946-6-13

  • 24

    RyterS. W.ChoiA. M. (2010). Autophagy in the lung. Proc. Am. Thorac. Soc7 (1), 1321. 10.1513/pats.200909-101JS

  • 25

    RyterS. W.NakahiraK.HaspelJ. A.ChoiA. M. (2012). Autophagy in pulmonary diseases. Annu. Rev. Physiol74 (4), 377401. 10.1164/rccm.201512-2468SO10.1146/annurev-physiol-020911-153348

  • 26

    SreenivasmurthyS. G.LiuJ. Y.SongJ. X.YangC. B.MalampatiS.WangZ. Y.et al (2017). Neurogenic traditional Chinese medicine as a promising strategy for the treatment of alzheimer's disease. Int. J. Mol. Sci18 (2), 272. 10.3390/ijms18020272

  • 27

    TasdemirE.MaiuriM. C.GalluzziL.VitaleI.Djavaheri-MergnyM.D’AmelioM.et al (2008). Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol10, 676687. 10.1038/ncb1730

  • 28

    TorreL. A.BrayF.SiegelR. L.FerlayJ.Lortet-TieulentJ.JemalA. (2015). Global cancer statistics, 2012. CA A Cancer J. Clin65 (2), 87108. 10.3322/caac.21262

  • 29

    WangH.ZhangW. X.ChengY. T.ZhangX. Y.XueN. N.WuG. R.et al (2018). Design, synthesis and biological evaluation of ligustrazine-flavonoid derivatives as potential anti-tumor agents. Molecules23 (9), 2187. 10.3390/molecules23092187

  • 30

    WangS.XuX.HuY.LeiT.LiuT. (2019). Sotetsuflavone induces autophagy in non-small cell lung cancer through blocking PI3K/Akt/mTOR signaling pathway in vivo and in vitro. Front. Pharmacol10, 1460. 10.3389/fphar.2019.01460

  • 31

    WangX.ShenY.WangS.LiS.ZhangW.LiuX.et al (2017). PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res45, W356W360. 10.1093/nar/gkx374

  • 32

    XiaoZ.WangC. Q.ZhouM. H.HuS. S.JiangY.HuangX. R.et al (2019). Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: a meta-analysis of 31 randomized controlled trials following the PRISMA guidelines. J. Ethnopharmacol228, 110122. 10.1016/j.jep.2018.09.024

  • 33

    XuF.CuiW. Q.WeiY.CuiJ.QiuJ.HuL. L.et al (2018). Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J. Exp. Clin. Canc. Res37 (1), 207. 10.1186/s13046-018-0878-0

  • 34

    XuH. D.QinZ. H. (2019). Beclin 1, Bcl-2 and autophagy. Adv. Exp. Med. Biol1206, 109126. 10.1007/978-981-15-0602-4_5

  • 35

    XuH. Y.ZhangY. Q.LiuZ. M.ChenT.LvC. Y.TangS. H.et al (2019). ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res47 (D1), D976D982. 10.1093/nar/gky987

  • 36

    XueR.FangZ.ZhangM.YiZ.WenC.ShiT. (2012). TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res41, D1089D1095. 10.1093/nar/gks1100

  • 37

    YuY.HouL.SongH.XuP.SunY.WuK. (2017). Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells. Mol. Cell. Biochem424 (1), 173183. 10.1007/s11010-016-2853-4

  • 38

    ZhangH. W.HuJ. J.FuR. Q.LiuX.ZhangY. H.LiJ.et al (2018). Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells. Sci. Rep8 (1), 11255. 10.1038/s41598-018-29308-7

  • 39

    ZhouF.YangY.XingD. (2011). Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J278 (3), 403413. 10.1111/j.1742-4658.2010.07965.x

  • 40

    ZhuX. Y.GuoD. W.LaoQ. C.XuY. Q.MengZ. K.XiaB.et al (2019). Sensitization and synergistic anti-cancer effects of Furanodiene identified in zebrafish models. Sci. Rep9 (1), 4541. 10.1038/s41598-019-40866-2

Summary

Keywords

key word: effective components, traditional Chinese medicine, astragali radix, lung cancer, autophagy, potential targets, network pharmacology, cell membrane immobilized chromatography

Citation

Yang B, Yang N, Chen Y, Zhu M, Lian Y, Xiong Z, Wang B, Feng L and Jia X (2021) An Integrated Strategy for Effective-Component Discovery of Astragali Radix in the Treatment of Lung Cancer. Front. Pharmacol. 11:580978. doi: 10.3389/fphar.2020.580978

Received

07 July 2020

Accepted

17 November 2020

Published

14 January 2021

Volume

11 - 2020

Edited by

Hai Yu Xu, China Academy of Chinese Medical Sciences, China

Reviewed by

Yonghua Zhao, University of Macau, China

Wenyi Kang, Henan University, China

Updates

Copyright

*Correspondence: Liang Feng, ; Xiaobin Jia,

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics